Comparison of SIMOA and VEUS technologies for serum neurofilament light chain measurement in multiple sclerosis.

Autor: Pelisek O; Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic; Centre of Clinical Neurosciences, University of Ostrava, Ostrava, Czech Republic., Kusnierova P; Institute of Laboratory Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic; Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czech Republic., Hradilek P; Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic; Centre of Clinical Neurosciences, University of Ostrava, Ostrava, Czech Republic; Institute of Laboratory Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Horakova J; Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic., Svub K; Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic., Siprova K; Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic., Sobek O; Topelex Ltd., Laboratory for CSF, Neuroimmunology, Pathology and Special Diagnostics, Prague, Czech Republic., Ganesh A; Departments of Clinical Neurosciences and Community Health Sciences, the Hotchkiss Brain Institute and the O'Brien Institute for Public Health, University of Calgary Cumming School of Medicine, Calgary, Canada., Hanzlikova P; Department of Radiology, University Hospital Ostrava, Ostrava, Czech Republic., Volny O; Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic; Centre of Clinical Neurosciences, University of Ostrava, Ostrava, Czech Republic., Revendova KZ; Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic; Centre of Clinical Neurosciences, University of Ostrava, Ostrava, Czech Republic. Electronic address: kamila.revendova@fno.cz.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2024 Oct; Vol. 90, pp. 105815. Date of Electronic Publication: 2024 Aug 11.
DOI: 10.1016/j.msard.2024.105815
Abstrakt: Introduction: The gold standard for serum neurofilament light chain (sNfL) determination is the single molecule array (SIMOA), the use of which is limited by availability and cost. The VEUS method is a fully automated, user-friendly diagnostic system requiring no sample preparation, with high reported sensitivity, multiplexing capability, and rapid diagnostics. The aim of this study was to compare the SIMOA and VEUS methods for determining sNfL levels in patients with multiple sclerosis (MS).
Methodology: A single-centre cross-sectional study was conducted at the MS Centre of University Hospital Ostrava. Patients were enrolled in the study from January 18 to January 31, 2024. Inclusion criteria were: 1) diagnosis of MS according to the revised 2017 McDonald criteria, 2) age ≥18 years, and 3) signed informed consent. The NF-light V2 diagnostic kit (SIMOA, Quanterix) and the Singleplex Neurology assay kit (VEUDx, EZDiatech) were used to determine sNfL concentrations. The two methods were compared by use of Spearman correlation, Passing-Bablok regression, and Bland-Altman analysis.
Results: A total of 49 patients were included in the study, of whom 39 (79.6 %) were female. The median sNfL concentration was 7.73 (IQR 5.80-9.93) ng/L determined by SIMOA and 1.31 (IQR 1.18-1.65) ng/L by VEUS. We did not find a correlation between SIMOA and VEUS (r s = 0.025, p = 0.866). Passing-Bablok regression demonstrated a systematic and proportional difference between the two methods. A significant disagreement between them was also confirmed by the Bland-Altman plots. On average, sNfL values measured by SIMOA were 3.56 ng/L (95 % CI 0.78 to 6.34) higher than those measured by VEUS.
Conclusion: Our investigation uncovered noteworthy disparities between the SIMOA and VEUS techniques in determining sNfL levels. Specifically, the VEUS technique systematically produces lower estimates of sNFL levels. This substantial variance emphasizes the importance of carefully evaluating assay methods when quantifying sNfL.
Competing Interests: Declaration of competing interest O Volny reports a research support from the The Quality assurance frameworks for health services and patient safety based on systematic support for data-driven and informed decision-making. A Ganesh reports salary support from the Heart and Stroke Foundation of Canada New Investigator Award relevant to the published work. He also reports consulting fees and honoraria from Atheneum, AlphaSights, MD Ana- lytics, MyMedicalPanel, Creative Research Designs, CTC Communications Corp, Alexion, Biogen, and Servier Canada; research support from Alberta Innovates, the Alzheimer Society of Canada, Campus Alberta Neuroscience, Brain Canada, the Canadian Cardiovascular Society, Panmure House, the Government of Canada INOVAIT and New Frontiers in Research Fund programs, and the Canadian Institutes of Health Research; stock/stock options from SnapDx and Let's Get Proof (Collavidence Inc) – all outside the scope of the published work. All other authors have no conflict of interest to declare.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: